US-CONGRESS BILLS-119hr9790ih: Modernizing Opioid Treatment Access Act 2.0 of 2026
The Modernizing Opioid Treatment Access Act 2.0 of 2026 expands access to opioid treatment by allowing certain practitioners to prescribe controlled substances for maintenance or detoxification treatment without a separate DATA waiver, and modifies reporting requirements to PDMPs.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 21, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon enactment; compliance expected within 90 days of passage.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Eliminates the requirement for a separate DATA 2000 waiver for prescribing buprenorphine for opioid use disorder; expands the types of practitioners who can prescribe; requires PDMP query before prescribing; modifies dispensing limits and reporting obligations.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies
What you must do
Update policies and procedures to accommodate new prescriber types and PDMP query requirements; train staff on changes to dispensing limits and reporting.
Deadline
Effective upon enactment; compliance expected within 90 days of passage.
Source: https://www.govinfo.gov/app/details/BILLS-119hr9790ih
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- US-CONGRESS BILLS-119hr9599ih: Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act; SECURE 340B Act
- DEA issues 4th extension of telehealth controlled substance flexibilities as debate enters 6th year - Fierce Healthcare
- DEA Adds Second Step to Reporting Procedure for Controlled Substance Theft or Loss - Reed Smith LLP
- Murphy signs bill scheduling tianeptine as Schedule II controlled substance in New Jersey - WRNJ Radio
- TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.